Metraipolis › archive › dc_11f7f428cb4f

Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer — Europe PMC PMID:41899536

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41899536
DOI
10.3390/cancers18060932
License (as archived)
solo-consultazione
Archived
2026-11-04T10:18:29.750Z
SHA-256 of the archived text
e774808c06600368972e57d0ee804d03a06025ce0fda653fb072caa9108a8450
Stable URL of this page
https://metraipolis.com/documento/dc_11f7f428cb4f

How to cite

Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer — Europe PMC PMID:41899536 — Europe PMC (en), https://europepmc.org/article/MED/41899536 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_11f7f428cb4f (Metraipolis archive dc_11f7f428cb4f, sha256 e774808c06600368972e57d0ee804d03a06025ce0fda653fb072caa9108a8450)
BibTeX
@misc{dc11f7f428cb4f,
  title = {Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer — Europe PMC PMID:41899536},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41899536},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_11f7f428cb4f; sha256 e774808c06600368972e57d0ee804d03a06025ce0fda653fb072caa9108a8450},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41899536. Agents can read the archived copy with the MCP tool read_document.